Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monthly C.E.R.A. versus epoetin beta or darbepoetin alfa for hemoglobin maintenance in hemodialysis patients with chronic kidney disease
2007-004014-13Phase 3Active
- Sponsor
- Roche
- Start
- Apr 2008
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anemia of chronic kidney disease comparing Monthly methoxy polyethylene glycol-epoetin beta, Epoetin beta and Darbepoetin alfa (3 arms). Primary endpoint: Maintenance of mean hemoglobin within target range. Started Apr 2008; status: active.
02
Drugs
methoxy polyethylene glycol-epoetin betaepoetin betadarbepoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2007-004014-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004014-13.